Clinical Trials
Advancing the field through innovative therapeutic approaches
The Blood and Marrow Transplantation & Cellular Therapy Division is committed to advancing the field through a robust portfolio of clinical trials that explore innovative therapeutic approaches, including novel cellular immunotherapies and CAR T-cell therapies. As a proud member of the Blood and Marrow Transplant Clinical Trials Network of the National Cancer Institute, our clinical investigators play a pivotal role in designing and implementing studies ranging from early-phase trials to pivotal late-phase research.
These studies aim to evaluate treatment efficacy, understand immune responses, and ensure the smooth translation of research findings into the most advanced patient care available today. Our clinical trials at the Stanford Cancer Center focus on new treatments and complementary therapies, ultimately driving the development of more effective treatment strategies for hematologic diseases and related disorders.
BMT-CT Clinical Trials Recruiting
Showing 1 - 6 of 18 trials
-
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Stanford is currently accepting patients for this trial. -
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Stanford is currently not accepting patients for this trial. -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Stanford is currently accepting patients for this trial. -
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Stanford is currently accepting patients for this trial. -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford is currently accepting patients for this trial. -
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Stanford is currently accepting patients for this trial.
